This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.
Get full access to this article
View all access options for this article.
References
1.
TeunissenC.E., DijkstraC.D., PolmanC.H., HoogervorstE.L., von BergmannK., LutjohannD.Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients. Neurosi Lett.2003; 347: 159–162.
2.
StuveO., YoussefS., SteinmanL., ZamvilS.S.Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol.2003; 16: 393–401.
3.
NeuhausO., Strasser-FuchsS., FazekasF.Statins as immunomodulators: Comparison with interferon-beta 1b in MS. Neurology.2002; 59: 990–997.
4.
ToghaM., KarvighS.A., NabaviM.Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta la: A double-blind randomized controlled trial. Mult Scler.2010; 16(7): 848–854.
5.
SorensenP.S., LyckeJ., ErälinnaJ.P.; SIMCOMBIN Study Investigators. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): A placebo-controlled randomised phase 4 trial. Lancet Neurol.2011; 10(8): 691–701.
6.
BhardwajS., ColemanC.I., SobierajD.M.Efficacy of statins in combination with interferon therapy in multiple sclerosis: A meta-analysis. Am J Health Syst Pharm.2012; 69(17): 1494–1499.
